Investigational Drug Information for Tetrahydrocannabivarin
✉ Email this page to a colleague
What is the drug development status for Tetrahydrocannabivarin?
Tetrahydrocannabivarin is an investigational drug.
There have been 3 clinical trials for Tetrahydrocannabivarin.
The most recent clinical trial was a Phase 2 trial, which was initiated on February 1st 2014.
The most common disease conditions in clinical trials are Diabetes Mellitus, Type 2, Diabetes Mellitus, and Alopecia Areata. The leading clinical trial sponsors are GW Research Ltd, Gregory L Smith, MD, MPH, and [disabled in preview].
Summary for Tetrahydrocannabivarin
| US Patents | 0 |
| International Patents | 0 |
| US Patent Applications | 1,285 |
| WIPO Patent Applications | 1,095 |
| Japanese Patent Applications | 26 |
| Clinical Trial Progress | Phase 2 (2014-02-01) |
| Vendors | 0 |
Recent Clinical Trials for Tetrahydrocannabivarin
| Title | Sponsor | Phase |
|---|---|---|
| Androgenetic Alopecia Treatment Using Varin and Cannabidiol Rich Topical Hemp Oil: A Case Series | Gregory L Smith, MD, MPH | Early Phase 1 |
| A Study of GWP42004 as Add on to Metformin in the Treatment of Participants With Type 2 Diabetes | GW Research Ltd | Phase 2 |
| GWMD1092 - GWP42003 : GWP42004 Together Plus Alone in Type II Diabetes | GW Research Ltd | Phase 2 |
Clinical Trial Summary for Tetrahydrocannabivarin
Top disease conditions for Tetrahydrocannabivarin
Top clinical trial sponsors for Tetrahydrocannabivarin
US Patents for Tetrahydrocannabivarin
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
